Virax Biolabs Group (NASDAQ:VRAX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Virax Biolabs Group (NASDAQ:VRAX) in a report published on Friday, Marketbeat.com reports. HC Wainwright currently has a $1.00 price target on the stock, down from their previous price target of $3.00.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $1.00.

Virax Biolabs Group Price Performance

Shares of Virax Biolabs Group stock opened at $0.36 on Friday. The company’s fifty day simple moving average is $0.43 and its two-hundred day simple moving average is $0.63. Virax Biolabs Group has a 12-month low of $0.31 and a 12-month high of $2.61.

Virax Biolabs Group (NASDAQ:VRAX) last announced its earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The firm had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.